Literature DB >> 23837188

Approach to the patient: the adult with congenital adrenal hyperplasia.

Richard J Auchus1, Wiebke Arlt.   

Abstract

The most common form of congenital adrenal hyperplasia is steroid 21-hydroxylase deficiency (21OHD). When the nonclassical (mild) form is included, 21OHD is the most common genetic disease in human beings. With the advent of pharmaceutical preparation of glucocorticoids starting in the 1960s and newborn screening starting in the 1990s, the majority of children with 21OHD are reaching adulthood, which has yielded a cohort of patients with, in essence, a new disease. Only recently have some data emerged from cohorts of adults with 21OHD, and in some centers, experience with the management of these patients is growing. These patients suffer from poor health, infertility, characteristic tumors in the adrenal glands and gonads, and consequences of chronic glucocorticoid therapy. Their care is fragmented and inconsistent, and many stop taking their medications out of frustration. Internal medicine residents and endocrinology fellows receive little training in their care, which further discourages their seeking medical attention. Adults with 21OHD have a different physiology from patients with Addison's disease or other androgen excess states, and their needs are different than those of young children with 21OHD. Consequently, their care requires unorthodox treatment and monitoring strategies foreign to most endocrine practitioners. Our goal for this article is to review their physiology, complications, and needs in order to develop rational and effective treatment and monitoring strategies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23837188      PMCID: PMC3701266          DOI: 10.1210/jc.2013-1440

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  63 in total

Review 1.  Congenital adrenal hyperplasia.

Authors:  Phyllis W Speiser; Perrin C White
Journal:  N Engl J Med       Date:  2003-08-21       Impact factor: 91.245

2.  Normal female infants born of mothers with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  J C Lo; V M Schwitzgebel; J B Tyrrell; P A Fitzgerald; S L Kaplan; F A Conte; M M Grumbach
Journal:  J Clin Endocrinol Metab       Date:  1999-03       Impact factor: 5.958

3.  Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency.

Authors:  Nicole Reisch; Marina Willige; Denise Kohn; Hans-Peter Schwarz; Bruno Allolio; Martin Reincke; Marcus Quinkler; Stefanie Hahner; Felix Beuschlein
Journal:  Eur J Endocrinol       Date:  2012-04-18       Impact factor: 6.664

4.  The long term outcome of feminizing genital surgery for congenital adrenal hyperplasia: anatomical, functional and cosmetic outcomes, psychosexual development, and satisfaction in adult female patients.

Authors:  Nike M M L Stikkelbroeck; Catharina C M Beerendonk; Wim N P Willemsen; Conny A Schreuders-Bais; Wouter F J Feitz; Paul N M A Rieu; Ad R M M Hermus; Barto J Otten
Journal:  J Pediatr Adolesc Gynecol       Date:  2003-10       Impact factor: 1.814

5.  Serum cortisol and 17-hydroxyprogesterone interrelation in classic 21-hydroxylase deficiency: is current replacement therapy satisfactory?

Authors:  E Charmandari; D R Matthews; A Johnston; C G Brook; P C Hindmarsh
Journal:  J Clin Endocrinol Metab       Date:  2001-10       Impact factor: 5.958

6.  The challenge of delivering endocrine care and successful transition to adult services in adolescents with congenital adrenal hyperplasia: experience in a single centre over 18 years.

Authors:  Helena Gleeson; Joanne Davis; Julie Jones; Elaine O'Shea; Peter E Clayton
Journal:  Clin Endocrinol (Oxf)       Date:  2013-01       Impact factor: 3.478

7.  Repeated successful induction of fertility after replacing hydrocortisone with dexamethasone in a patient with congenital adrenal hyperplasia and testicular adrenal rest tumors.

Authors:  Hedi L Claahsen-van der Grinten; Barto J Otten; Fred C G J Sweep; Ad R M M Hermus
Journal:  Fertil Steril       Date:  2007-05-22       Impact factor: 7.329

8.  Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency.

Authors:  Zeina Chakhtoura; Anne Bachelot; Dinane Samara-Boustani; Jean-Charles Ruiz; Bruno Donadille; Jérôme Dulon; Sophie Christin-Maître; Claire Bouvattier; Marie-Charles Raux-Demay; Philippe Bouchard; Jean-Claude Carel; Juliane Leger; Frédérique Kuttenn; Michel Polak; Philippe Touraine
Journal:  Eur J Endocrinol       Date:  2008-04-07       Impact factor: 6.664

9.  High prevalence of reduced fecundity in men with congenital adrenal hyperplasia.

Authors:  Nicole Reisch; Linda Flade; Michael Scherr; Marietta Rottenkolber; Francesco Pedrosa Gil; Martin Bidlingmaier; Hans Wolff; Hans-Peter Schwarz; Marcus Quinkler; Felix Beuschlein; Martin Reincke
Journal:  J Clin Endocrinol Metab       Date:  2009-03-03       Impact factor: 5.958

10.  Glucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia.

Authors:  T S Han; R H Stimson; D A Rees; N Krone; D S Willis; G S Conway; W Arlt; B R Walker; R J Ross
Journal:  Clin Endocrinol (Oxf)       Date:  2013-02       Impact factor: 3.478

View more
  39 in total

1.  Bilateral adrenal incidentaloma caused by 21-hydroxylase deficiency in an adult.

Authors:  Sun Hee Kim; Ji Hyun Park
Journal:  Endocrine       Date:  2014-09-02       Impact factor: 3.633

2.  Profiles of 21-Carbon Steroids in 21-hydroxylase Deficiency.

Authors:  Adina F Turcu; Juilee Rege; Robert Chomic; Jiayan Liu; Hiromi K Nishimoto; Tobias Else; Andreas G Moraitis; Ganesh S Palapattu; William E Rainey; Richard J Auchus
Journal:  J Clin Endocrinol Metab       Date:  2015-04-07       Impact factor: 5.958

3.  Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency.

Authors:  Richard J Auchus; Elizabeth O Buschur; Alice Y Chang; Gary D Hammer; Carole Ramm; David Madrigal; George Wang; Martha Gonzalez; Xu Steven Xu; Johan W Smit; James Jiao; Margaret K Yu
Journal:  J Clin Endocrinol Metab       Date:  2014-04-29       Impact factor: 5.958

Review 4.  Imaging features of poorly controlled congenital adrenal hyperplasia in adults.

Authors:  H K Kok; M Sherlock; N A Healy; O Doody; P Govender; W C Torreggiani
Journal:  Br J Radiol       Date:  2015-07-02       Impact factor: 3.039

Review 5.  Cross-sectional imaging features of unusual adrenal lesions: a radiopathological correlation.

Authors:  Ali Devrim Karaosmanoglu; Omer Onder; Can Berk Leblebici; Cenk Sokmensuer; Deniz Akata; Mustafa Nasuh Ozmen; Musturay Karcaaltincaba
Journal:  Abdom Radiol (NY)       Date:  2021-03-18

6.  A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia.

Authors:  Diala El-Maouche; Deborah P Merke; Maria G Vogiatzi; Alice Y Chang; Adina F Turcu; Elizabeth G Joyal; Vivian H Lin; Lauren Weintraub; Marianne R Plaunt; Pharis Mohideen; Richard J Auchus
Journal:  J Clin Endocrinol Metab       Date:  2020-08-01       Impact factor: 5.958

7.  Working memory performance is reduced in children with congenital adrenal hyperplasia.

Authors:  Wendy V Browne; Peter C Hindmarsh; Vickie Pasterski; Ieuan A Hughes; Carlo L Acerini; Debra Spencer; Sharon Neufeld; Melissa Hines
Journal:  Horm Behav       Date:  2014-12-09       Impact factor: 3.587

Review 8.  Steroid biomarkers in human adrenal disease.

Authors:  Juilee Rege; Adina F Turcu; Tobias Else; Richard J Auchus; William E Rainey
Journal:  J Steroid Biochem Mol Biol       Date:  2019-01-29       Impact factor: 4.292

9.  Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia.

Authors:  Ashwini Mallappa; Aikaterini A Nella; Ninet Sinaii; Hamsini Rao; Verena Gounden; Ashley F Perritt; Parag Kumar; Alexander Ling; Chia-Ying Liu; Steven J Soldin; Deborah P Merke
Journal:  Clin Endocrinol (Oxf)       Date:  2018-08-08       Impact factor: 3.478

Review 10.  Management of adolescents with congenital adrenal hyperplasia.

Authors:  Deborah P Merke; Dix P Poppas
Journal:  Lancet Diabetes Endocrinol       Date:  2013-11-15       Impact factor: 32.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.